# Phil Rivers Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phil-rivers-technology

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.philrivers.com
- Total disclosed funding: $59M
- Latest round: Series A (Aug 5, 2026)
- Investors on record: 8

## About

Based in Beijing, China, and founded in 2015, PHIL RIVERS TECHNOLOGY Co., Ltd., trading as Phil Rivers Technology, is a biotechnology company focusing on AI pharmaceutical R&D. The company's founder, Chunming Zhang is an associate researcher at the Institute of Computing Technology, Chinese Academy of Sciences. In August 2026, it raised nearly CNY 200 million in a Series A2 funding round.

The company has built three AI tool platforms including the biomedical knowledge AI platform, virtual clinical trial platform, and AI platform for quantitative assessment of cell function. Its AI platforms can be applied in six scenarios such as new targets, new mechanisms of action, new biomarkers, design clinical trial schemes, predict clinical trial results, and new indications. It is also advancing multiple FIC (First in Class) pipelines including pancreatic cancer, liver cancer, and breast cancer.

The company generates revenue from the sales of medicines, service for clinical trial, and clinical treatment.

The company will use the Series A2 funding to support its continued production of high-value innovative IPs and global asset layout, as well as the upgrade of the AI4S platform driven by the life world model. Also, it will continuously improve the basic model matrix, including knowledge models, genome models, signaling pathway models, virtual cell models, and lesion world models, promote the construction of AI intelligent agents and experimental verification systems, and accelerate the industrialization of original targets, innovative drug pipelines, and virtual clinical trials.

## Funding rounds

- Series A, Aug 5, 2026, $30M — Casstar Capital, Sansure Biotech Inc., Zhangjiang Science & Technology Venture Capital
- Series A, Dec 16, 2025, $14M — CAS Investment Management, Zheshang Venture Capital
- Series A, Jul 8, 2022, $15M — Insight Capital, Beijing Highthink Pharmaceutical Technology Service Co., Ltd., Beijing Taiya Yusong Private Equity Fund Management

## Investors

- Insight Capital — Series A
- Beijing Highthink Pharmaceutical Technology Service Co., Ltd. — Series A
- Beijing Taiya Yusong Private Equity Fund Management — Series A
- CAS Investment Management (https://capitalatlas.ai/funds/cas-investment-management) — Series A
- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series A
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series A
- Sansure Biotech Inc. — Series A
- Zhangjiang Science & Technology Venture Capital (https://capitalatlas.ai/funds/zhangjiang-science-technology-venture-capital) — Series A